Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone + metformin versus metformin as base therapy, each combined with SGLT-2 inhibitors and GLP-1 receptor agonists, in newly diagnosed type 2 diabetes with fatty liver
ChiCTR2200059806Phase 4Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Xinjiang Medical University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of pioglitazone and metformin in type 2 diabetes mellitus (T2DM) and steatosis (2 arms), sponsored by The Fifth Affiliated Hospital of Xinjiang Medical University. Primary endpoints: Blood glucose and Glycosylated hemoglobin. Planned start May 2022; status: not yet recruiting.
02
Drugs
pioglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)steatosis
Beyond the preview
Go deeper on ChiCTR2200059806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059806.